가도테리돌

가도테리돌 · prohance · ICG-Maleimide · Gadolinol · ICG-Hydrazide · 0))- · ICG HZ · SQ 32692

https://huagongshe.com/ko/chemical/60714

식별자 및 물리적 특성

CAS No.	120066-54-8
분자식	C17H29GdN4O7
평균 분자량	558.7 g/mol
단동위원소 질량	559.12774 g/mol
SMILES	CC(O)CN1CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)[O-])CC1.[Gd+3]
InChIKey	DPNNNPAKRZOSMO-UHFFFAOYSA-K
PubChem CID	60714
현지명	가도테리돌

화학 및 물리적 성질

극성 표면적	154
수소 결합 공여자 수	1
수소 결합 수용자 수	11
회전 가능 결합 수	5
무거운 원자 수	29
형식 전하	0
복잡도	471
LogP(분배 계수)	log Kow = -3.68 (octanol/water)logP = -1.98 (butanol/water), at pH 7
밀도	Osmolality (37 °C): 630 mOsM/kg waterviscosity (cP): 2.0 (20 °C), 1.3 (37 °C)density at 25 °C 1.140. /Gadoteridol injection/
Color/Form	White solid obtained as an aggregate clump of fine needle-like micro-crystals from methanol/acetone
용해도	In water, 737 mg/mLSolubility (mg/mL): methanol 119, isopropanol 41, dimethylformamide 10.1, acetonitrile 6.1, methylene chloride 5.2, ethyl acetate 0.5, acetone 0.4, hexane 0.2, toluene 0.3PBS (pH 7.2): 10 mg/ml
녹는점	>225 °C188-193 °C
Other Experimental Properties	Hydrophilic
저장 조건	Store at -20°C
물리적 상태	고체
색상	White to off-white
주요 응용	의약품(소분자)
InChI	InChI=1S/C17H31N4O7.Gd/c1-14(22)10-18-2-4-19(11-15(23)24)6-8-21(13-17(27)28)9-7-20(5-3-18)12-16(25)26/h14H,2-13H2,1H3,(H,23,24)(H,25,26)(H,27,28)/q-1+4/p-3
InChIKey	JOJFJDKAWWEUPD-UHFFFAOYSA-K
SMILES	CC1CN23CCN45CCN67CCN8(CC2)CC(=O)[O-][Gd+3]3486([O-]C(=O)C5)([O-]C(=O)C7)O1

안전 및 규제

FDA 요건	The Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including gadoteridol, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.
보관 조건	ProHance (Gadoteridol) Injection should be stored at 25 °C (77 °F) excursions permitted to 15-30 °C (59- 86 °F). Protect from light. Do not freeze.
처리 방법	SRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.
환경 거동	TERRESTRIAL FATE: The elements of the lanthanide series typically occur as the +3 ion either in solution or in compounds(1). Based on the Gd3+/Gd reduction potential of -2.28 V(1), gadolinium(III) ions do not undergo oxidation-reduction reactions under normal environmental conditions(SRC). Gadolinium ions are likely to adsorb to soils(SRC). In general, metal cations in solution are attracted to the negatively charged surfaces of soil particles(2). The extent of adsorption of metal ions to soils depends on the pH, the mineral content, and organic content of the soil(2). Gadolinium compounds do not volatilize from dry or moist soil surfaces due to their ionic character(SRC).
독성 요약	IDENTIFICATION AND USE: Gadoteridol is used as injectable contrast medium for Magnetic Resonance Imaging (MRI). HUMAN EXPOSURE AND TOXICITY: Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs. The risk for NSF appears highest among patients with: chronic, severe kidney disease , or acute kidney injury. Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (older than 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing. For patients at highest risk for NSF, do not exceed the recommended ProHance dose and allow a sufficient period of time for elimination of the drug from the body prior to re-administration. The possibility of a reaction, including serious, life threatening, or fatal, anaphylactic or cardiovascular reactions, or other idiosyncratic reactions, should always be considered, especially in those patients with a history of a known clinical hypersensitivity or a history of asthma or other allergic respiratory disorders. The literature describe a case of vasovagal response and anaphylactoid reaction during iv administration of gadoteridol. In an in vitro test, gadoteridol did not demonstrate any potential to hemolyze human erythrocytes when incubated in high concentrations with whole blood, suggesting there is little probability gadoteridol will cause hemolysis in vivo. ANIMAL STUDIES: Gadopentetate dimeglumine (Magnevist), gadoteridol (ProHance), gadodiamide (Omniscan), and gadoversetamide (Optimark) were evaluated at standard concentration and compared wi

용도

Gadoteridol is used as an MRI contrast chelating agent.

일반 설명

Gadoteridol is a nonionicclear, colorless to slightly yellow, gadolinium-based contrastagent indicated to visualize lesions with abnormal vascularityin the CNS, head, and neck. It is a hypertonic solutionwith an osmolality of 2.2 times that of plasma. Clinical enhancementof images occurs primarily when using T1-weighted sequences.